Lupus (SLE) clinical trials

40 trials changed in the last 30 days: 5 stopped, 15 with notable changes, 20 with minor changes only.

1. Stopped

   LNP023 · Active Lupus Nephritis Class III-IV, +/- V

   Trial terminated

   Also in this update: Trial sites reduced: 103 → 74 locations; Study completion date changed from estimate of Sep 28, 2028 to Oct 1, 2026

   Novartis Pharmaceuticals·Phase 2· NCT05268289· Registry history of NCT05268289 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Stopped

   YTS109 Cell in R/R Systemic Lupus Erythematosus

   Trial terminated

   Also in this update: Final enrollment: 2 participants — 6% of the 36 planned; Study completion date changed from estimate of Apr 25, 2027 to Apr 25, 2026

   China Immunotech (Beijing) Biotechnology Co., Ltd.·Phase 1· NCT06943937· Registry history of NCT06943937 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

3. Stopped

   NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

   Trial status changed: Not Yet Recruiting → Terminated

   Also in this update: Phase changed: not applicable → Early Phase 1; Primary completion date changed from estimate of Sep 1, 2027 to Apr 1, 2026

   Base Therapeutics (Shanghai) Co., Ltd.·Early Phase 1· NCT07083349· Registry history of NCT07083349 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

4. Stopped

   Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory…Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

   Trial status changed: Recruiting → Withdrawn

   Beijing Boren Hospital·Phase 1· NCT07361094· Registry history of NCT07361094 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

5. Stopped

   LVIVO-TaVec400 · Relapsed/Refractory Autoimmune Diseases

   Withdrawn before enrolling

   Also in this update: Primary completion date changed from estimate of Sep 20, 2028 to Sep 23, 2026

   Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·Early Phase 1· NCT07583030· Registry history of NCT07583030 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

6. Notable

   in vivo CAR-T · TI-0032-III Injection · Relapsed and Refractory…in vivo CAR-T · TI-0032-III Injection · Relapsed and Refractory Autoimmune Diseases

   Primary completion pushed from May 1, 2026 to May 1, 2027

   Also in this update: Study completion pushed from Jan 30, 2027 to May 30, 2027

   Therorna·Phase 1· NCT07413341· Registry history of NCT07413341 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

7. Notable

   SIRIUS-SLE LTE · Ianalumab · Systemic Lupus Erythematosus…SIRIUS-SLE LTE · Ianalumab · Systemic Lupus Erythematosus (SIRIUS-SLE Extension)

   Primary completion pushed from Apr 8, 2030 to Apr 3, 2034

   Also in this update: Trial sites expanded: 143 → 162 locations; Study completion pushed from Apr 5, 2032 to Oct 2, 2034

   Novartis Pharmaceuticals·Phase 3· NCT06133972· Registry history of NCT06133972 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

8. Notable

   EMERALD · Litifilimab (BIIB059) Injections and it's Effects on…EMERALD · Litifilimab (BIIB059) Injections and it's Effects on Symptoms · Systemic Lupus Erythematosus (SLE)

   Primary and study completion pushed from Mar 29, 2030 to May 3, 2032

   Biogen·Phase 3· NCT05352919· Registry history of NCT05352919 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

9. Notable

   KITE-363 · Refractory Autoimmune Diseases

   Primary and study completion pushed from Jul 2029 to Sep 2030

   Kite, A Gilead Company·Phase 1· NCT07038447· Registry history of NCT07038447 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

10. Notable

    SynBioSe-2 · Synergetic B-cell Immunomodulation in SLE - 2nd Study

    Primary completion pushed from Jun 7, 2024 to Jun 22, 2026

    Also in this update: Trial completed

    Leiden University Medical Center·Phase 3· NCT03747159· Registry history of NCT03747159 on ClinicalTrials.gov (opens the registry)

    Oct 7, 2026

11. Notable

    BRIDGE Pain · Biopsychosocial Risk Influences on the Development…BRIDGE Pain · Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain

    Primary endpoint(s) modified

    Children's Hospital Medical Center, Cincinnati·Not specified· NCT07602595· Registry history of NCT07602595 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

12. Notable

    Healthy Adult Participants and · Autoimmune Disease to Test How…Healthy Adult Participants and · Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

    Recruitment opened

    Otsuka Pharmaceutical Development & Commercialization, Inc.·Phase 1· NCT07649265· Registry history of NCT07649265 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

13. Notable

    ROSY-S · Rollover Study · Completed a Previous Clinical Study…ROSY-S · Rollover Study · Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

    Recruitment opened

    Also in this update: Trial sites expanded: 41 → 128 locations

    AstraZeneca·Phase 3· NCT07691970· Registry history of NCT07691970 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

14. Notable

    LOTUS · Outcomes in Chinese Patients Treated With Anifrolumab Who…LOTUS · Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

    Recruitment opened

    Also in this update: Trial sites expanded: 44 → 71 locations

    AstraZeneca·Phase 3· NCT07751848· Registry history of NCT07751848 on ClinicalTrials.gov (opens the registry)

    Sep 22, 2026

15. Notable

    Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years…Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

    Recruitment opened

    Also in this update: Trial sites expanded: 0 → 32 locations

    AstraZeneca·Phase 2· NCT07630714· Registry history of NCT07630714 on ClinicalTrials.gov (opens the registry)

    Sep 22, 2026

16. Notable

    Lupus Nephritis Care Pathway

    Recruitment opened

    Duke University·Not applicable· NCT07783152· Registry history of NCT07783152 on ClinicalTrials.gov (opens the registry)

    Oct 19, 2026

17. Notable

    CART-NEL · CD19 CAR-T Cell Therapy (TranspoCART19)…CART-NEL · CD19 CAR-T Cell Therapy (TranspoCART19) · Refractory Lupus Nephritis

    Recruitment opened

    Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz·Phase 1/2· NCT07799116· Registry history of NCT07799116 on ClinicalTrials.gov (opens the registry)

    Oct 1, 2026

18. Notable

    BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

    Recruitment opened

    Peking University Third Hospital·Early Phase 1· NCT07301164· Registry history of NCT07301164 on ClinicalTrials.gov (opens the registry)

    Sep 23, 2026

19. Notable

    Called PF-08154225 · Autoimmune Diseases

    Start date pushed from Oct 10, 2026 to Nov 19, 2026

    Pfizer·Phase 1/2· NCT07782450· Registry history of NCT07782450 on ClinicalTrials.gov (opens the registry)

    Oct 1, 2026

20. Notable

    LCAR-AIO · Relapsed/Refractory Systemic Lupus Erythematosus

    Final enrollment: 3 participants — 9% of the 34 planned

    Also in this update: Trial completed; Primary completion date changed from estimate of Sep 30, 2027 to Jun 6, 2026

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·Early Phase 1· NCT06653556· Registry history of NCT06653556 on ClinicalTrials.gov (opens the registry)

    Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.